Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.130 +0.020 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
58 Biggest Movers From Yesterday
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
Why Shares of Cassava Sciences Rose 15% Today
Additional data is promising. But will investors trust it? 
Via The Motley Fool
B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'
B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of... 
Via Benzinga
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off. 
Via InvestorPlace
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
Cassava said patients who received its Alzheimer's drug showed improved cognition. 
Via Investor's Business Daily
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate... 
Via Benzinga
Cassava Sciences Can Recover Despite Harsh Allegations
SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down. 
Via InvestorPlace
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year. 
Via Investor's Business Daily
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right. 
Via InvestorPlace
46 Biggest Movers From Yesterday
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares... 
Via Benzinga
Cassava Stock Is a Bold Play That Could Pay Off Soon
Bears are attacking SAVA stock as it questions the quality of its clinical data and try to stop its study for treating Alzheimer’s disease. 
Via InvestorPlace
A Reply To Dr Biks on $SAVA PTau-181
Data by BruinAnteater @BruinStocks - Twitter, @BruinAnteaterStock - Stocktwits A Quick Introduction Hello, allow me to introduce myself. On twitter I am known as @BruinStocks, and... 
Via Benzinga
What Happens When A Biotech Stock Blows Up: How Our Hedged Portfolio Method Limited The Damage With Cassava Sciences
Screen capture via Cassava Sciences' video for their Simulfilam Alzheimer's disease treatment. When A Biotech Stock Goes The Wrong Way In our last post (Corona Doom... 
Via Benzinga
When A Biotech Stock Blows Up
How to limit the damage when something goes wrong. We can't always be right, which is why we hedge.. 
Via Talk Markets
Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy
Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well. Even after it 57%+ price haircut, approach SAVA stock cautiously. 
Via InvestorPlace
Topics Fraud
Exposures Legal
Better Buy: Biogen vs. Cassava Sciences
These two biotechs are going after a significant market: Alzheimer's. 
Via The Motley Fool
Cassava Plummets — Again — After CEO Denies Data Manipulation Claims
Cassava CEO Remi Barbier denied allegations of data manipulation in the firm's Alzheimer's research on Friday. But SAVA stock tumbled, again. 
Via Investor's Business Daily
Cassava CEO Goes Offensive Over Data Allegations
Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based... 
Via Benzinga
Exposures Product Safety
Fraud Allegations Are Unlikely to Keep Cassava Stock Down
Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy. 
Via InvestorPlace
Topics Fraud
Exposures Legal Product Safety
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. 
Via InvestorPlace
Here's How You Handle a Volatile Stock Like Cassava Sciences
Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed. 
Via The Motley Fool
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) stock rose 16.51% to $7.83 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 675.7K shares... 
Via Benzinga
Wait to See How the Cassava Sciences Allegations Pan Out
Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result. Is this a buy-on-the-dip moment? 
Via InvestorPlace
Insiders Like Cassava Sciences, Which Might Be Good News
Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today? 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's stock is trading at a volume of 143.0K shares as of... 
Via Benzinga
Why This Cassava Sciences Analyst Is Dropping Coverage
The selling in Cassava Sciences, Inc. (NASDAQ:SAVA) stock ... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.